Professor Jonathan Emberson
Jonathan Emberson
BA, MSc, PhD
Professor of Medical Statistics and Epidemiology
- MRC Population Health Research Unit Programme Leader
- NDPH Deputy Director of Graduate Studies
- MSc in Global Health Science Module Lead: Clinical Trials and Meta-Analysis
Jonathan is Professor of Medical Statistics and Epidemiology within the Nuffield Department of Population Health. After graduating in Mathematics in 1998, he studied statistics and epidemiology at MSc and PhD level before joining the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) in 2004.
His main research involves studying the causes and prevention of cardiovascular diseases through the design, conduct and analysis of large-scale observational cohort studies, randomised controlled trials, and individual-participant-data meta-analyses of both types of study. In particular, he is the UK Principal Investigator and MRC Population Health Research Unit (MRC-PHRU) Programme Leader for the Mexico City Prospective Study, a blood-based prospective cohort study of 150,000 Mexican adults followed for more than 15 years.
Recent publications
-
Body composition and risk of vascular-metabolic mortality risk in 113,000 Mexican men and women without prior chronic disease
Journal article
EMBERSON J. et al, (2022), Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
-
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Journal article
Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801
-
Human genetics uncovers
MAP3K15
as an obesity-independent therapeutic target for diabetes
Journal article
Nag A. et al, (2022), Science Advances, 8
-
Adiposity and NMR-measured lipid and metabolic biomarkers among 30,000 Mexican adults.
Journal article
Aguilar-Ramirez D. et al, (2022), Commun Med (Lond), 2
-
Empagliflozin in Patients with Chronic Kidney Disease.
Journal article
EMPA-KIDNEY Collaborative Group None. et al, (2022), N Engl J Med